Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 3/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.35 |
| ▸ | CNR1 | P21554 | 3/20 | 0.34 |
| ▸ | CNR2 | P34972 | 2/20 | 0.34 |
| ▸ | GCGR | P47871 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.33 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.33 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5222107 | 0.93 | PTGS1 (0.39) | SLC6A4SLC6A2SLC6A3MAPK14GCGR | |
| SCHEMBL5226664 | 0.83 | PTGS2 (0.48) | MAPK14PTGS1 | |
| SCHEMBL5223501 | 0.79 | TRPA1 (0.44) | MAPK14GCGRALDH1A1KMT2ANPSR1 | |
| SCHEMBL5226799 | 0.76 | SYK (0.44) | SLC6A4MAPK14ALDH1A1KMT2ANPSR1 | |
| SCHEMBL5223530 | 0.75 | MAPK14 (0.46) | MAPK14GCGRALDH1A1MAPK13MAPK12 | |
| SCHEMBL5222047 | 0.73 | SYK (0.42) | MAPK14ALDH1A1MEN1KMT2ANPSR1 | |
| SCHEMBL5222256 | 0.73 | PTGS1 (0.46) | MAPK14CNR1CNR2GCGRALDH1A1 | |
| SCHEMBL5223261 | 0.73 | GSK3B (0.42) | ALDH1A1MEN1KMT2ANPSR1MAPK1 | |
| SCHEMBL5221631 | 0.72 | SYK (0.42) | MAPK14GCGRALDH1A1MEN1KMT2A | |
| SCHEMBL5224594 | 0.72 | ADORA2A (0.41) | ALDH1A1MEN1KMT2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1300399-B1 | PHENYLPYRIDAZINE DERIVATIVES AND DRUGS CONTAINING THE SAME | KOWA CO (JP) | 2007-08-22 | — | — | EP | claimed |
| US-6664256-B1 | Interleukin- 1 beta inhibitors | KOWA CO., LTD. (JP) | 2003-12-16 | — | — | US | claimed |
| EP-1300399-A1 | PHENYLPYRIDAZINE DERIVATIVES AND DRUGS CONTAINING THE SAME | Kowa Co., Ltd. (JP) | 2003-04-09 | — | — | EP | claimed |
| EP-1379525-B1 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | NPS PHARMA INC (US) | 2007-10-10 | — | — | EP | disclosed |
| EP-1300399-B1 | PHENYLPYRIDAZINE DERIVATIVES AND DRUGS CONTAINING THE SAME | KOWA CO (JP) | 2007-08-22 | — | — | EP | disclosed |
| US-7112595-B2 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | NPS PHARMACEUTICALS, INC. (US) | 2006-09-26 | — | — | US | disclosed |
| US-20060189661-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2006-08-24 | — | — | US | disclosed |
| US-20050154027-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | NPS PHARMACEUTICALS, INC. | 2005-07-14 | — | — | US | disclosed |
| US-6664256-B1 | Interleukin- 1 beta inhibitors | KOWA CO., LTD. (JP) | 2003-12-16 | — | — | US | disclosed |
| US-6660753-B2 | For therapy of stroke, head trauma, anoxic injury, ischemic injury, hypoglycemia, epilepsy, pain, migraine headaches, Parkinson's disease, senile dementia, Huntington's Chorea, anxiety, and Alzheimer's disease | NPS PHARMACEUTICALS, INC. | 2003-12-09 | — | — | US | disclosed |
| EP-1300399-A1 | PHENYLPYRIDAZINE DERIVATIVES AND DRUGS CONTAINING THE SAME | Kowa Co., Ltd. (JP) | 2003-04-09 | — | — | EP | disclosed |
| US-20030055085-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2003-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154027-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM2, GRIN2A, GRM1 | SLC6A4 244/4885SLC6A2 317/4885SLC6A3 174/4885 |
| US-20030055085-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM2, GRIN2A, GRM1 | SLC6A4 244/4885SLC6A2 317/4885SLC6A3 174/4885 |
| US-20060189661-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM2, GRIN2A, GRM1 | SLC6A4 244/4885SLC6A2 317/4885SLC6A3 174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.